Cargando…

Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine

The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) project designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia, identified three drug mechanisms of particular interest: dopaminergic, cholinerg...

Descripción completa

Detalles Bibliográficos
Autor principal:	Koola, Maju Mathew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824953/ https://www.ncbi.nlm.nih.gov/pubmed/27069875 http://dx.doi.org/10.1016/j.scog.2016.02.001

Ejemplares similares

Galantamine-memantine combination effective in dementia: Translate to dementia praecox?
por: Koola, Maju Mathew, et al.
Publicado: (2018)

Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity
por: Koola, Maju Mathew, et al.
Publicado: (2018)

Cytokines in Schizophrenia: Hope or Hype?
por: Koola, Maju Mathew
Publicado: (2016)

Methodological Issues in Cytokine Measurement in Schizophrenia
por: Koola, Maju Mathew
Publicado: (2016)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity
por: Lopes, João P, et al.
Publicado: (2013)

Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine
por: Forrest, C.M., et al.
Publicado: (2015)

Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
por: Ovejero-Benito, María C., et al.
Publicado: (2022)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer’s Disease
por: Reggiani, Angelo M., et al.
Publicado: (2016)

Psychosocioeconomic Study of Medically Unexplained Physical Symptoms
por: Koola, Maju Mathew, et al.
Publicado: (2012)

Imbalanced Kynurenine Pathway in Schizophrenia
por: Kegel, Magdalena E, et al.
Publicado: (2014)

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano, Osamu, et al.
Publicado: (2013)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
por: Li, Dan-Dan, et al.
Publicado: (2019)

Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study
por: Lee, Jung Goo, et al.
Publicado: (2012)

Association of Lyme Disease and Schizoaffective Disorder, Bipolar Type: Is it Inflammation Mediated?
por: Mattingley, David William, et al.
Publicado: (2015)

Dyke-Davidoff-Masson syndrome presenting with bipolar I mania with psychosis
por: Kumari, Pooja, et al.
Publicado: (2018)

The Effect of Memantine Versus Folic Acid on Cognitive Impairment in Patients with Schizophrenia: A Randomized Clinical Trial
por: Hosseini, Seyed Ahmad, et al.
Publicado: (2023)

Critics on "Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study"
por: Pae, Chi-Un
Publicado: (2013)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice
por: Liu, Yi, et al.
Publicado: (2018)

Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI
por: Leijenaar, Jolien F., et al.
Publicado: (2020)

Tackling Negative Symptoms of Schizophrenia with Memantine
por: Paraschakis, Antonios
Publicado: (2014)

Memantine in neurological disorders – schizophrenia and depression
por: Czarnecka, Kamila, et al.
Publicado: (2021)

Memantine Attenuates Alzheimer’s Disease-Like Pathology and Cognitive Impairment
por: Wang, Xiaochuan, et al.
Publicado: (2015)

Role of Spirituality in the Management of Major Depression and Stress-Related Disorders
por: Varghese, Sajoy P., et al.
Publicado: (2021)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Changes in electrophysiological markers of cognitive control after administration of galantamine
por: Gascoyne, Lauren E., et al.
Publicado: (2018)

The kynurenine pathway relates to post‐acute COVID‐19 objective cognitive impairment and PASC
por: Cysique, Lucette A., et al.
Publicado: (2023)

Mild cognitive disorder and depression: treatment with combination of galantamine and escitalopram
por: Zarra, Julio, et al.
Publicado: (2010)

Effects of inflammation on the kynurenine pathway in schizophrenia — a systematic review
por: Pedraz-Petrozzi, Bruno, et al.
Publicado: (2020)

Potential drug targets in the kynurenine pathway to treat acute schizophrenia
por: Malhotra, Ayush, et al.
Publicado: (2021)

Clinical predictors of kynurenine pathway aberrations in schizophrenia and bipolar disorder
por: Skorobogatov, K., et al.
Publicado: (2022)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study
por: Hager, Klaus, et al.
Publicado: (2016)

Kynurenine Pathway as a New Target of Cognitive Impairment Induced by Lead Toxicity During the Lactation
por: Ramirez Ortega, Daniela, et al.
Publicado: (2020)

An Open-Label Trial of Memantine for Cognitive Impairment in Patients with Posttraumatic Stress Disorder
por: Ramaswamy, Sriram, et al.
Publicado: (2015)

The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors
por: Hughes, Tamera D., et al.
Publicado: (2022)

Long-term efficacy and safety of galantamine in outpatients with mild cognitive disorder
por: Zarra, Julio, et al.
Publicado: (2010)

A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia
por: Büki, Alexandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_043tb4heac2gobn1f0ntgl70o8